The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Adc Therapeutics SA’s stock clocked out at $2.89, down -7.37% from its previous closing price of $3.12. In other words, the price has decreased by -$7.37 from its previous closing price. On the day, 1.06 million shares were traded. ADCT stock price reached its highest trading level at $3.1 during the session, while it also had its lowest trading level at $2.84.
Ratios:
To gain a deeper understanding of ADCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share. On Dec 04 ’24, another insider, Redmile Group, LLC, who serves as the 10% Owner of the company, sold 25,352 shares for $2.07 each. As a result, the insider received 52,479 and left with 15,566,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 324434304 and an Enterprise Value of 541814272. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.78. Its current Enterprise Value per Revenue stands at 7.146 whereas that against EBITDA is -4.364.
Stock Price History:
The Beta on a monthly basis for ADCT is 1.95, which has changed by -0.12951809 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $3.97, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is -3.40%, while the 200-Day Moving Average is calculated to be 30.73%.
Shares Statistics:
It appears that ADCT traded 753.55K shares on average per day over the past three months and 614900 shares per day over the past ten days. A total of 99.18M shares are outstanding, with a floating share count of 77.65M. Insiders hold about 21.71% of the company’s shares, while institutions hold 74.08% stake in the company. Shares short for ADCT as of 1752537600 were 5464561 with a Short Ratio of 7.25, compared to 1749772800 on 4528219. Therefore, it implies a Short% of Shares Outstanding of 5464561 and a Short% of Float of 6.0.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $17.86M. It ranges from a high estimate of $18.5M to a low estimate of $17.5M. As of the current estimate, Adc Therapeutics SA’s year-ago sales were $17.41MFor the next quarter, 5 analysts are estimating revenue of $18.32M. There is a high estimate of $19.2M for the next quarter, whereas the lowest estimate is $17.6M.
A total of 6 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $79.8M, while the lowest revenue estimate was $75.8M, resulting in an average revenue estimate of $77.42M. In the same quarter a year ago, actual revenue was $70.84MBased on 5 analysts’ estimates, the company’s revenue will be $83.39M in the next fiscal year. The high estimate is $116.6M and the low estimate is $68.6M.
